You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
藥捷安康(02617.HK)高開15%屢破頂 上市不足三個月累飆35倍 市值超中生(01177.HK)石藥(01093.HK)
連日急升的內地生物藥企藥捷安康-B(02617.HK)今日(16日)高開15%,報477.2元屢創上市高,市前成交2.55萬股,涉資1,216.86萬元。 公司於上周一(8日)獲調入港股通標的證券名單。其於6月23日上市,上市價13.15元,當時集資淨額1.61億元。以現價計,上市不足三個月,較上市價高出35.2倍。最新市值逾1,890億元,較藍籌中生(01177.HK)逾1,640億元、石藥(01093.HK)的約1,237億元更高,但低於翰森(03692.HK)的約2,206億元市值。 其上市集資所得約90%用於為核心產品恩戈替尼(Tinengotinib,TT-00420)正在進行單藥治療CCA的多區域註冊III期臨床試驗提供資金;約10%用於一般營運資金及一般公司用途。恩戈替尼是一種獨特的多靶點激(酉每)抑制劑,主要靶向三個關鍵通路。恩戈替尼正進行兩項關鍵性/註冊臨床試驗,用於治療在過往接受FGFR抑制劑治療後疾病發生進展的膽管癌。 藥捷安康日前宣布,核心產品替恩戈替尼聯合氟維司群治療經治失敗的激素受體陽性(HR+)且人表皮生長因子受體2陰性或低表達(HER2-)的復發或轉移性乳腺癌II期臨床試驗,已獲國家藥品監督管理局的臨床默示許可。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account